In pancreatic ductal adenocarcinoma, inhibition of HCK can target TAMs, thereby reducing the infiltration of immune cells, alleviating immunosuppression and improving chemotherapy efficacy (Creeden et al., 2020). The gene discussed is HCK; the disease is pancreatic ductal adenocarcinoma.